» Articles » PMID: 38673434

Concept and Diagnostic Challenges of Renal-Limited Hemophagocytic Syndrome/Macrophage Activation Syndrome

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Apr 27
PMID 38673434
Authors
Affiliations
Soon will be listed here.
Abstract

Hemophagocytic syndrome/macrophage activation syndrome (HPS/MAS) is a serious clinical condition that frequently leads to multiple organ failure, including acute kidney injury (AKI). Although the pathogenesis of AKI is not yet fully understood, it is believed to result from uncontrolled activation of the immune system involving macrophages and cytotoxic lymphocytes. Renal histology in HPS/MAS often presents with characteristic foamy glomerular lesions (glomerular lipidosis) with massive macrophage infiltration, known as histiocytic glomerulopathy. In this review, we introduce the recently proposed concept of renal-limited HPS/MAS as a novel etiology of histiocytic glomerular lipidosis. Patients with renal-limited HPS/MAS often develop AKI but do not fulfill the diagnostic criteria for HPS/MAS because their systemic manifestations are less severe. Therefore, the diagnosis largely depends on characteristic histological findings, that is, diffuse and global glomerular accumulation of foamy macrophages and cytotoxic lymphocytes accompanied by the interaction of these cells as well as the exclusion of various differential diseases. Although there are no established therapeutic regimens, these patients receive various types of therapies, including high-dose glucocorticoids, immunosuppressants, or anti-interleukin-1 drug, and generally achieve favorable outcomes. We summarized the concept, diagnostic challenges, and recent topics of this disease entity and discussed treatment options based on our own experiences.

References
1.
Stephan J, Zeller J, Hubert P, Herbelin C, Dayer J, Prieur A . Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993; 11(4):451-6. View

2.
Shakoory B, Geerlinks A, Wilejto M, Kernan K, Hines M, Romano M . The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis Rheumatol. 2023; 75(10):1714-1732. PMC: 11040593. DOI: 10.1002/art.42636. View

3.
Roccatello D, Sciascia S, Barreca A, Naretto C, Alpa M, Quattrocchio G . Renal involvement as a unique manifestation of hemophagocytic syndrome. Front Med (Lausanne). 2022; 9:796121. PMC: 9579315. DOI: 10.3389/fmed.2022.796121. View

4.
Kinoshita M, Nakashima M, Nakashima H, Seki S . Immune Mechanisms Underlying Susceptibility to Endotoxin Shock in Aged Hosts: Implication in Age-Augmented Generalized Shwartzman Reaction. Int J Mol Sci. 2019; 20(13). PMC: 6651521. DOI: 10.3390/ijms20133260. View

5.
Aulagnon F, Lapidus N, Canet E, Galicier L, Boutboul D, Peraldi M . Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am J Kidney Dis. 2014; 65(6):851-9. DOI: 10.1053/j.ajkd.2014.10.012. View